188 related articles for article (PubMed ID: 38245602)
1. Inherent genome instability underlies trisomy 21-associated myeloid malignancies.
Chen CC; Silberman RE; Ma D; Perry JA; Khalid D; Pikman Y; Amon A; Hemann MT; Rowe RG
Leukemia; 2024 Mar; 38(3):521-529. PubMed ID: 38245602
[TBL] [Abstract][Full Text] [Related]
2. Synergistic roles of DYRK1A and GATA1 in trisomy 21 megakaryopoiesis.
Sit YT; Takasaki K; An HH; Xiao Y; Hurtz C; Gearhart PA; Zhang Z; Gadue P; French DL; Chou ST
JCI Insight; 2023 Oct; 8(23):. PubMed ID: 37906251
[TBL] [Abstract][Full Text] [Related]
3. Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of
Barwe SP; Sebastian A; Sidhu I; Kolb EA; Gopalakrishnapillai A
Cells; 2022 Feb; 11(4):. PubMed ID: 35203280
[TBL] [Abstract][Full Text] [Related]
4. Pluripotent stem cell model of early hematopoiesis in Down syndrome reveals quantitative effects of short-form GATA1 protein on lineage specification.
Matsuo S; Nishinaka-Arai Y; Kazuki Y; Oshimura M; Nakahata T; Niwa A; Saito MK
PLoS One; 2021; 16(3):e0247595. PubMed ID: 33780474
[TBL] [Abstract][Full Text] [Related]
5. Generation of CHOPi-008-B, a euploid iPSC line from a patient with Trisomy 21 and a GATA1 mutation.
Takasaki K; Kumar SS; Gagne A; French DL; Chou ST
Stem Cell Res; 2023 Oct; 72():103198. PubMed ID: 37677872
[TBL] [Abstract][Full Text] [Related]
6. [Myeloid proliferations related to Down syndrome].
Hasegawa D
Rinsho Ketsueki; 2019; 60(9):1299-1307. PubMed ID: 31597856
[TBL] [Abstract][Full Text] [Related]
7. Generation of 2 isogenic clones from a patient with Trisomy 21 and a GATA1 mutation.
Takasaki K; Kumar SS; Gagne A; French DL; Chou ST
Stem Cell Res; 2023 Jun; 69():103098. PubMed ID: 37084616
[TBL] [Abstract][Full Text] [Related]
8. Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update.
Bhatnagar N; Nizery L; Tunstall O; Vyas P; Roberts I
Curr Hematol Malig Rep; 2016 Oct; 11(5):333-41. PubMed ID: 27510823
[TBL] [Abstract][Full Text] [Related]
9. Germline GATA1s-generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype.
Hasle H; Kline RM; Kjeldsen E; Nik-Abdul-Rashid NF; Bhojwani D; Verboon JM; DiTroia SP; Chao KR; Raaschou-Jensen K; Palle J; Zwaan CM; Nyvold CG; Sankaran VG; Cantor AB
Blood; 2022 May; 139(21):3159-3165. PubMed ID: 34758059
[TBL] [Abstract][Full Text] [Related]
10. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
[TBL] [Abstract][Full Text] [Related]
11. Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia.
Kanezaki R; Toki T; Terui K; Xu G; Wang R; Shimada A; Hama A; Kanegane H; Kawakami K; Endo M; Hasegawa D; Kogawa K; Adachi S; Ikeda Y; Iwamoto S; Taga T; Kosaka Y; Kojima S; Hayashi Y; Ito E
Blood; 2010 Nov; 116(22):4631-8. PubMed ID: 20729467
[TBL] [Abstract][Full Text] [Related]
12. Hematological disorders in children with Down syndrome.
Triarico S; Trombatore G; Capozza MA; Romano A; Mastrangelo S; Attinà G; Maurizi P; Ruggiero A
Expert Rev Hematol; 2022 Feb; 15(2):127-135. PubMed ID: 35184659
[TBL] [Abstract][Full Text] [Related]
13. Stepwise GATA1 and SMC3 mutations alter megakaryocyte differentiation in a Down syndrome leukemia model.
Arkoun B; Robert E; Boudia F; Mazzi S; Dufour V; Siret A; Mammasse Y; Aid Z; Vieira M; Imanci A; Aglave M; Cambot M; Petermann R; Souquere S; Rameau P; Catelain C; Diot R; Tachdjian G; Hermine O; Droin N; Debili N; Plo I; Malinge S; Soler E; Raslova H; Mercher T; Vainchenker W
J Clin Invest; 2022 Jul; 132(14):. PubMed ID: 35587378
[TBL] [Abstract][Full Text] [Related]
14. GATA1 and cooperating mutations in myeloid leukaemia of Down syndrome.
Garnett C; Cruz Hernandez D; Vyas P
IUBMB Life; 2020 Jan; 72(1):119-130. PubMed ID: 31769932
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the understanding of transient abnormal myelopoiesis in Down syndrome.
Watanabe K
Pediatr Int; 2019 Mar; 61(3):222-229. PubMed ID: 30593694
[TBL] [Abstract][Full Text] [Related]
16. Transient abnormal myelopoiesis of a newborn not associated with chromosome 21 abnormalities or GATA1 mutations.
Nakashima MO; Shetty S; Chicka M; Flagg A; Eng C; Cotta CV
Pediatr Blood Cancer; 2015 Feb; 62(2):353-355. PubMed ID: 25175265
[TBL] [Abstract][Full Text] [Related]
17. GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia.
Maroz A; Stachorski L; Emmrich S; Reinhardt K; Xu J; Shao Z; Käbler S; Dertmann T; Hitzler J; Roberts I; Vyas P; Juban G; Hennig C; Hansen G; Li Z; Orkin S; Reinhardt D; Klusmann JH
Leukemia; 2014 Jun; 28(6):1259-70. PubMed ID: 24336126
[TBL] [Abstract][Full Text] [Related]
18. Down syndrome-associated haematopoiesis abnormalities created by chromosome transfer and genome editing technologies.
Kazuki Y; Yakura Y; Abe S; Osaki M; Kajitani N; Kazuki K; Takehara S; Honma K; Suemori H; Yamazaki S; Sakuma T; Toki T; Shimizu R; Nakauchi H; Yamamoto T; Oshimura M
Sci Rep; 2014 Aug; 4():6136. PubMed ID: 25159877
[TBL] [Abstract][Full Text] [Related]
19. Modeling Transient Abnormal Myelopoiesis Using Induced Pluripotent Stem Cells and CRISPR/Cas9 Technology.
Barwe SP; Sidhu I; Kolb EA; Gopalakrishnapillai A
Mol Ther Methods Clin Dev; 2020 Dec; 19():201-209. PubMed ID: 33102613
[TBL] [Abstract][Full Text] [Related]
20. Clinical, cytogenetic, and molecular analyses of 17 neonates with transient abnormal myelopoiesis and nonconstitutional trisomy 21.
Yuzawa K; Terui K; Toki T; Kanezaki R; Kobayashi A; Sato T; Kamio T; Kudo K; Sasaki S; Endo M; Ozono S; Nomura K; Ito E
Pediatr Blood Cancer; 2020 Apr; 67(4):e28188. PubMed ID: 32020774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
